California Senate Committee Approves Psychedelics Legalization Bill
California Senate Public Safety Committee approves of SB-58, legalizing the possession and use of specific psychedelics.
In March 2023, a new piece of legislation was approved in the California Senate (1). The bill, SB-58 (2), legalizes possession of certain psychedelics and use of the substances. Senator Scott Wiener (D) refiled the bill back in December 2022, not long after an extensive version was halted in the last session. In its approval hearing, the Senate Public Safety Committee ratified the bill with a 3-1 vote. It will now head on to the Appropriations Committee.
Some of the psychedelics SB-58 legalizes are psilocybin, psilocyn, dimenthyltryptamine (DMT), ibogaine, and mescaline for either facilitated or personal use. Synthetic psychedelics such as lysergic acid diethylamide (LSD) and 3,4-Methylenedioxymethamphetamine (MDMA) which is also known as ecstasy or molly, are not legalized in this bill but were originally included in the previous expansive bill. The new legislation also provides ““group counseling and community-based healing” involving the entheogenic substances (1).
“These are not addictive drugs. And these are drugs that have significant potential in helping people to navigate and to become healthy who are experiencing mental health challenges, substance use challenges,” Wiener mentioned at the approval hearing (1).
“We know that cities in California and elsewhere have passed resolutions to categorize enforcement of these particular criminal laws as the lowest law enforcement priority,” he said. “This is an important step for California. This is about making sure that people have access to substances that they need that are not addictive.”
A separate bill from Assembly member Marie Waldron (R) was introduced in February 2023 (1), with the goal to legalize psychedelics-assisted therapy for military veterans by allowing licensed clinical counselors to administer controlled substances (not limited to psilocybin, LSD, MDMA, ibogaine, and ketamine) to veterans for the treatment of post-traumatic stress disorder (PTSD), traumatic brain injuries, or addiction.
In regards to Wiener’s SB-58 bill, advocates are highly optimistic due to more time to consider the proposal from when it was first introduced and also the growing momentum behind psychedelics.
References
Ep 26: Innovations in Drying and Curing to Protect Flower Quality
May 27th 2025In this latest installment of Noid Knowledge, we are joined by Dr. Allison Justice, Founder and CEO of the Hemp Mine, and David Sandelman COO, CTO & Co-Founder of Cannatrol. Here, Allison and David discuss innovations in cannabis drying and curing, focusing on the Cannatrol technology which controls vapor pressure, preserving trichome integrity, and flower quality. Additionally, Allison shares how the Cannabis Research Center and Coalition (CRC) is transition to an open-source model to support cultivators, researchers, and home growers.
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
